NCT06596915View on ClinicalTrials.gov

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 30, 2026

Conditions
Non-Small Cell Lung CancerPancreatic AdenocarcinomaBreast CancerMelanoma
Interventions
DRUG

BA1302

BA1302 administered intravenously

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Shandong Boan Biotechnology Co., Ltd

INDUSTRY